Skip to main content
Erschienen in: Clinical and Translational Oncology 4/2018

21.08.2017 | Research Article

Treatment of childhood astrocytomas with irinotecan and cisplatin

verfasst von: J. Mora, S. Perez-Jaume, O. Cruz

Erschienen in: Clinical and Translational Oncology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Previously we described the outcome of children with spinal cord astrocytoma treated with irinotecan and cisplatin (I/C). We here report the review of the initial institutional experience using this combination for children with low-grade glioma (LGG).

Procedure

I/C chemotherapy consisted of weekly cisplatin (30 mg/m2) and irinotecan (50–65 mg/m2) for a total maximum of 16 doses, administered in an outpatient basis.

Results

Between November 2002 and December 2009, 46 children (median age 6.3 years; range 0.3–17.7) with glioma were treated. We here report the cohort of 31 patients with LGG. Patients received a median of 16 cycles of I/C (range 8–16). The overall objective response [complete response (CR) + partial response (PR)] and disease control (CR + PR + stable disease) rates to I/C treatment were 6.5% [95% confidence interval (CI), 0.8–21.4%] and 93.5% (95% CI 78.6–99.2%), respectively. Disease control persisted for a median of 65 months. Toxicity was predominantly myelosuppression only seen in heavily pretreated patients. Survival analysis shows 5-year event-free survival (EFS) of 54% and 5-year overall survival (OS) of 80%.

Conclusion

I/C chemotherapy produced disease control and clinical improvement in a majority of children with low-grade glioma, with manageable toxicity.
Literatur
1.
2.
Zurück zum Zitat Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol. 2001;3:152–8.CrossRefPubMedPubMedCentral Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol. 2001;3:152–8.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Louis DN, Ohgaki H, Wiestler OD, Webster WK. WHO classification of tumours of the central nervous system. Lyon: IARC; 2016. Louis DN, Ohgaki H, Wiestler OD, Webster WK. WHO classification of tumours of the central nervous system. Lyon: IARC; 2016.
4.
Zurück zum Zitat Sturm D, Pfister SM, Jones DTW. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J Clin Oncol. 2017;35:2370–7.CrossRefPubMed Sturm D, Pfister SM, Jones DTW. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J Clin Oncol. 2017;35:2370–7.CrossRefPubMed
5.
Zurück zum Zitat Gnekow AK, Falkenstein F, von Hornstein S, Zwiener I, Berkefeld S, Bison B, et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol. 2012;14:1265–84.CrossRefPubMedPubMedCentral Gnekow AK, Falkenstein F, von Hornstein S, Zwiener I, Berkefeld S, Bison B, et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol. 2012;14:1265–84.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Qaddoumi I, Sultan I, Broniscer A. Pediatric low-grade gliomas and the need for new options for therapy: why and how? Cancer Biol Ther. 2009;8:4–10.CrossRefPubMedPubMedCentral Qaddoumi I, Sultan I, Broniscer A. Pediatric low-grade gliomas and the need for new options for therapy: why and how? Cancer Biol Ther. 2009;8:4–10.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Mora J, Cruz O, Gala S, Navarro R. Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin. Neuro Oncol. 2007;9:39–46.CrossRefPubMedPubMedCentral Mora J, Cruz O, Gala S, Navarro R. Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin. Neuro Oncol. 2007;9:39–46.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Garzón M, García-Fructuoso G, Guillén A, Suñol M, Mora J, Cruz O. Low-grade gliomas in children. Single institutional experience in 198 cases. Childs Nerv Syst. 2015;31:1447–59.CrossRefPubMed Garzón M, García-Fructuoso G, Guillén A, Suñol M, Mora J, Cruz O. Low-grade gliomas in children. Single institutional experience in 198 cases. Childs Nerv Syst. 2015;31:1447–59.CrossRefPubMed
11.
Zurück zum Zitat Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:2641–7.CrossRefPubMedPubMedCentral Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:2641–7.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30:1358–63.CrossRefPubMed Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30:1358–63.CrossRefPubMed
13.
Zurück zum Zitat Gururangan S, Fisher MJ, Allen JC, Herndon JE 2nd, Quinn JA, Reardon DA, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007;9:161–8.CrossRefPubMedPubMedCentral Gururangan S, Fisher MJ, Allen JC, Herndon JE 2nd, Quinn JA, Reardon DA, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007;9:161–8.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Jakacki RI, Bouffet E, Adamson PC, Pollack IF, Ingle AM, Voss SD, et al. A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children’s Oncology Group phase 1 consortium study. Neuro Oncol. 2011;13:910–5.CrossRefPubMedPubMedCentral Jakacki RI, Bouffet E, Adamson PC, Pollack IF, Ingle AM, Voss SD, et al. A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children’s Oncology Group phase 1 consortium study. Neuro Oncol. 2011;13:910–5.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Ronghe M, Hargrave D, Bartels U, Tabori U, Vaidya S, Chandler C, et al. Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem. Pediatr Blood Cancer. 2010;55:471–7.CrossRefPubMed Ronghe M, Hargrave D, Bartels U, Tabori U, Vaidya S, Chandler C, et al. Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem. Pediatr Blood Cancer. 2010;55:471–7.CrossRefPubMed
16.
Zurück zum Zitat Scheinemann K, Bartels U, Tsangaris E, Hawkins C, Huang A, Dirks P, et al. Feasibility and efficacy of repeated chemotherapy for progressive pediatric low-grade gliomas. Pediatr Blood Cancer. 2011;57:84–8.CrossRefPubMed Scheinemann K, Bartels U, Tsangaris E, Hawkins C, Huang A, Dirks P, et al. Feasibility and efficacy of repeated chemotherapy for progressive pediatric low-grade gliomas. Pediatr Blood Cancer. 2011;57:84–8.CrossRefPubMed
17.
Zurück zum Zitat Lassaletta A, Scheinemann K, Zelcer SM, Hukin J, Wilson BA, Jabado N, et al. Phase II weekly vinblastine for chemotherapy-naïve children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium study. J Clin Oncol. 2016;34:3537–43.CrossRefPubMed Lassaletta A, Scheinemann K, Zelcer SM, Hukin J, Wilson BA, Jabado N, et al. Phase II weekly vinblastine for chemotherapy-naïve children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium study. J Clin Oncol. 2016;34:3537–43.CrossRefPubMed
18.
Zurück zum Zitat Krishnatry R, Zhukova N, Guerreiro Stucklin AS, Pole JD, Mistry M, Fried I, et al. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer. 2016;122:1261–9.CrossRefPubMed Krishnatry R, Zhukova N, Guerreiro Stucklin AS, Pole JD, Mistry M, Fried I, et al. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer. 2016;122:1261–9.CrossRefPubMed
19.
Zurück zum Zitat Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, et al. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin Cancer Res. 2001;7:68–73.PubMed Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, et al. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin Cancer Res. 2001;7:68–73.PubMed
20.
Zurück zum Zitat Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012;59:144–8.CrossRefPubMedPubMedCentral Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012;59:144–8.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012;30:2408–17.CrossRefPubMedPubMedCentral Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012;30:2408–17.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29:355–60.CrossRefPubMed Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29:355–60.CrossRefPubMed
23.
Zurück zum Zitat Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26:649–55.CrossRef Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26:649–55.CrossRef
24.
Zurück zum Zitat Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. Ototoxicity from high dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006;107:417–22.CrossRefPubMed Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. Ototoxicity from high dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006;107:417–22.CrossRefPubMed
25.
Zurück zum Zitat Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer. 2009;45:3213–9.CrossRefPubMed Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer. 2009;45:3213–9.CrossRefPubMed
26.
Zurück zum Zitat Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7–ethyl–10–(4–[1–piperidino]–1– piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 1997;39:187–91.CrossRefPubMed Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7–ethyl–10–(4–[1–piperidino]–1– piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 1997;39:187–91.CrossRefPubMed
27.
Zurück zum Zitat Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the duke experience. Neuro Oncol. 2002;4:102–8.CrossRefPubMedPubMedCentral Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the duke experience. Neuro Oncol. 2002;4:102–8.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Souid AK, Dubowy RL, Blaney SM, Hershon L, Sullivan J, McLeod WD, et al. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin Cancer Res. 2003;9:703–10.PubMed Souid AK, Dubowy RL, Blaney SM, Hershon L, Sullivan J, McLeod WD, et al. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin Cancer Res. 2003;9:703–10.PubMed
29.
Zurück zum Zitat Couec ML, André N, Thebaud E, Minckes O, Rialland X, Corradini N, et al. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. Pediatr Blood Cancer. 2012;59:34–8.CrossRefPubMed Couec ML, André N, Thebaud E, Minckes O, Rialland X, Corradini N, et al. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. Pediatr Blood Cancer. 2012;59:34–8.CrossRefPubMed
30.
Zurück zum Zitat Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, et al. Long-term efficacy and toxicity of bevacizumab based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer. 2013;60:776–82.CrossRefPubMed Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, et al. Long-term efficacy and toxicity of bevacizumab based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer. 2013;60:776–82.CrossRefPubMed
31.
Zurück zum Zitat Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28:3069–75.CrossRefPubMedPubMedCentral Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28:3069–75.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Doireau V, Grill J, Zerah M, Lellouch-Tubiana A, Couanet D, Chastagner P, et al. Chemotherapy for unresectable and recurrent intramedullary glial tumours in children. Brain Tumours Subcommittee of the French Society of Paediatric Oncology (SFOP). Br J Cancer. 1999;81:835–84.CrossRefPubMedPubMedCentral Doireau V, Grill J, Zerah M, Lellouch-Tubiana A, Couanet D, Chastagner P, et al. Chemotherapy for unresectable and recurrent intramedullary glial tumours in children. Brain Tumours Subcommittee of the French Society of Paediatric Oncology (SFOP). Br J Cancer. 1999;81:835–84.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002;20:4209–16.CrossRefPubMed Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002;20:4209–16.CrossRefPubMed
34.
Zurück zum Zitat Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed and progressive low-grade gliomas. J Neurosurg. 1997;86:747–54.CrossRefPubMed Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed and progressive low-grade gliomas. J Neurosurg. 1997;86:747–54.CrossRefPubMed
35.
Zurück zum Zitat Mahoney DH Jr, Cohen ME, Friedman HS, Kepner JL, Gemer L, Langston JW, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro Oncol. 2001;2:213–20.CrossRef Mahoney DH Jr, Cohen ME, Friedman HS, Kepner JL, Gemer L, Langston JW, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro Oncol. 2001;2:213–20.CrossRef
36.
Zurück zum Zitat Massimino M, Spreafico F, Riva D, Biassoni V, Poggi G, Solero C, et al. A lower-dose, lower-toxicity cisplatin and etoposide regimen for childhood progressive low-grade glioma. J Neuro Oncol. 2010;100:65–71.CrossRef Massimino M, Spreafico F, Riva D, Biassoni V, Poggi G, Solero C, et al. A lower-dose, lower-toxicity cisplatin and etoposide regimen for childhood progressive low-grade glioma. J Neuro Oncol. 2010;100:65–71.CrossRef
37.
Zurück zum Zitat Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012;14:790–7.CrossRefPubMedPubMedCentral Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012;14:790–7.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Moreno L, Bautista F, Ashley S, Duncan C, Zacharoulis S. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer. 2010;46:2253–9.CrossRefPubMed Moreno L, Bautista F, Ashley S, Duncan C, Zacharoulis S. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer. 2010;46:2253–9.CrossRefPubMed
39.
Zurück zum Zitat Gnekow AK, Walker DA, Kandels D, Picton S, Perilongo G, Grill J, et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma—a final report. Eur J Cancer. 2017;81:206–25.CrossRefPubMedPubMedCentral Gnekow AK, Walker DA, Kandels D, Picton S, Perilongo G, Grill J, et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma—a final report. Eur J Cancer. 2017;81:206–25.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Ater JL, Xia C, Mazewski CM, Booth TN, Freyer DR, Packer RJ, et al. Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the Children’s Oncology Group. Cancer. 2016;122:1928–36.CrossRefPubMedPubMedCentral Ater JL, Xia C, Mazewski CM, Booth TN, Freyer DR, Packer RJ, et al. Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the Children’s Oncology Group. Cancer. 2016;122:1928–36.CrossRefPubMedPubMedCentral
Metadaten
Titel
Treatment of childhood astrocytomas with irinotecan and cisplatin
verfasst von
J. Mora
S. Perez-Jaume
O. Cruz
Publikationsdatum
21.08.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 4/2018
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1741-z

Weitere Artikel der Ausgabe 4/2018

Clinical and Translational Oncology 4/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.